DE1795590A1 - New 7-amino-cephalosporanic acid esters - Google Patents

New 7-amino-cephalosporanic acid esters

Info

Publication number
DE1795590A1
DE1795590A1 DE19641795590 DE1795590A DE1795590A1 DE 1795590 A1 DE1795590 A1 DE 1795590A1 DE 19641795590 DE19641795590 DE 19641795590 DE 1795590 A DE1795590 A DE 1795590A DE 1795590 A1 DE1795590 A1 DE 1795590A1
Authority
DE
Germany
Prior art keywords
amino
new
acid esters
cephalosporanic acid
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
DE19641795590
Other languages
German (de)
Other versions
DE1795590B2 (en
DE1795590C3 (en
Inventor
Hans Dr Bickel
Rolf Dr Bosshardt
Bruno Dr Fechtig
Jakob Dr Urech
Ernst Dr Vischer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Ciba Geigy AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy AG filed Critical Ciba Geigy AG
Publication of DE1795590A1 publication Critical patent/DE1795590A1/en
Publication of DE1795590B2 publication Critical patent/DE1795590B2/en
Application granted granted Critical
Publication of DE1795590C3 publication Critical patent/DE1795590C3/en
Expired legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D501/00Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D501/14Compounds having a nitrogen atom directly attached in position 7
    • C07D501/16Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
    • C07D501/187-Aminocephalosporanic or substituted 7-aminocephalosporanic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B41PRINTING; LINING MACHINES; TYPEWRITERS; STAMPS
    • B41FPRINTING MACHINES OR PRESSES
    • B41F17/00Printing apparatus or machines of special types or for particular purposes, not otherwise provided for
    • GPHYSICS
    • G03PHOTOGRAPHY; CINEMATOGRAPHY; ANALOGOUS TECHNIQUES USING WAVES OTHER THAN OPTICAL WAVES; ELECTROGRAPHY; HOLOGRAPHY
    • G03CPHOTOSENSITIVE MATERIALS FOR PHOTOGRAPHIC PURPOSES; PHOTOGRAPHIC PROCESSES, e.g. CINE, X-RAY, COLOUR, STEREO-PHOTOGRAPHIC PROCESSES; AUXILIARY PROCESSES IN PHOTOGRAPHY
    • G03C3/00Packages of films for inserting into cameras, e.g. roll-films, film-packs; Wrapping materials for light-sensitive plates, films or papers, e.g. materials characterised by the use of special dyes, printing inks, adhesives
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Microelectronics & Electronic Packaging (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cephalosporin Compounds (AREA)

Description

CIBA-GEIGYAG, BASEL (SCHWEIZ) . 1795590CIBA-GEIGYAG, BASEL (SWITZERLAND). 1795590

Case 5.259/1-Vb 'Case 5.259 / 1-Vb '

DeutschlandGermany

Neue 7-Amino-cephalosporansaureester.New 7-amino-cephalosporanic acid esters.

Die-Herstellung von 7-Amino-cephalosporansäureestern g mit freier Äminogruppe aus Cephalosporin C bot bisher erheb- ■ erhebliche Schwierigkeiteni da die Amidgruppe des ß-Lactamringes gegenüber hydrolysierenden Agentien viel empfindlicher ist als die Amidgruppe in 7-Stellung, in der deutschen Anmeldung P 14 45 619.O-44 (5259/1-4) ist ein neues Verfahren zur Herstellung von 7-Amino-cephalosporansäureestern besehrieben.The production of 7-amino-cephalosporanic acid esters g with a free amino group from cephalosporin C has presented considerable difficulties so far because the amide group of the ß-lactam ring is much more sensitive to hydrolyzing agents than the amide group in the 7-position, in the German application P 14 45 619.O-44 (5259 / 1-4) describes a new process for the preparation of 7-amino-cephalosporanic acid esters.

Gegenstand der vorliegenden Teilanmeldung sind neue 7-Amino-cephalosporansäureester, nämlich Ester, deren Alkohol-The present divisional application relates to new 7-amino-cephalosporanic acid esters, namely esters whose alcohol

OFtIGiNALOFTIGiNAL

2 09812/17402 09812/1740

komponente Benzhydrol oder ρ,ρ-Dimethoxybenzhydrol ist. Diese Ester können nach dem in der genannten Anmeldung beschriebenen Verfahren hergestellt werden.component is benzhydrol or ρ, ρ-dimethoxybenzhydrol. These Esters can be prepared by the process described in the application mentioned.

Die Ester können durch Hydrolyse in die freie 7-Aminocephalosporansäure übergeführt werden, vorzugsweise mittels Trifluoressigsäure' und Anisol.The esters can be converted into the free 7-aminocephalosporanic acid by hydrolysis be converted, preferably by means of trifluoroacetic acid 'and anisole.

Die Erfindung wird in dem nachfolgenden Beispiel beschrieben. Die Temperaturen sind in Gelsiusgraden angegeben.The invention is described in the following example. The temperatures are given in degrees Celsius.

2 0 9812/1740 BAD ORIGINAL2 0 9812/1740 BAD ORIGINAL

Beispiel :Example :

12,6 g Cephalosporin C-di-benzhydrylester werden -in 2 Liter abs. Methylenchlorid gelöst, mit 2 ml 2-n. wässriger 'Essigsäure versetzt und 8 Tage bei 22 im Dunkeln stehen gelassen. Man dampft im Vakuum ein und nimmt den.-. Rückstand in einem Gemisch von 5 Teilen Toluol, 2 Teilen '' Essigester, 3 Teilen Alkohol und 3 Teilen 2-n.' wässriger Salzsäure auf. Nach vollständiger Lösung bei kräftigem Schütteln werden die Phasen getrennt und die Ünterphase mit zwei weiteren Oberphasen (5 Teile Toluol und 2 Teile r Essigester) ausgeschüttelt. Die 3 Oberphasen werden noch ^mal mit' Alkohol-2-n. Salzsäure (l:l) nachextrahiert. Die produkthaltigen Unterphasen werden vereinigt, mit 50-proz.12.6 g of Cephalosporin C-di-benzhydryl ester are -in 2 liters of abs. Dissolved methylene chloride, with 2 ml of 2-n. aqueous' acetic acid and left to stand for 8 days at 22 in the dark. It is evaporated in a vacuum and takes the.-. Residue in a mixture of 5 parts of toluene, 2 parts of '' ethyl acetate, 3 parts of alcohol and 3 parts of 2-n. ' aqueous hydrochloric acid. After complete dissolution, with vigorous shaking, the phases are separated and the Ünterphase with two other top phase (r 5 parts toluene and 2 parts Essigester) extracted. The 3 upper phases are again ^ times with 'alcohol-2-n. Hydrochloric acid (l: l) extracted. The product-containing sub-phases are combined with 50 percent.

wässriger Trikaliumphosphatlosung auf pH 6. gestellt und im Vakuum vom Alkohol befr'eit. Hierauf stellt man mit der (j Trikaliumphosphatlosung auf pH 8,0 und extrahiert ~$maX mit Essigester. Der über Natriumsulfat getrocknete Extrakt gibt beim Eindampfen den Y-Amino-cephalosporansäure-benzhydrylester, der aus Aether in zu Drusen vereinigten ' Nadeln kristallisiert; P. 122-124°; er zeigt im Dünn- . schichtchromatogramm an Silicagel im System.n-ButänolrEisessig (10:1) gesättigt mit V/asser einen Rf-Wert von 0,64 (schmutziggelber Pleck mit Ninhydrin-Collidin)Λaqueous tripotassium phosphate solution adjusted to pH 6 and freed from alcohol in vacuo. Then one introduces the (j Trikaliumphosphatlosung to pH 8.0 and extracted with ~ $ max Essigester The dried over sodium sulfate, the extract is by evaporation of the Y-amino-cephalosporanic acid benzhydryl ester, which combined from ether to drusen in 'needles crystallized. P 122-124 °; in the thin-layer chromatogram on silica gel in the system, n-butanol r glacial acetic acid (10: 1) saturated with water / water an Rf value of 0.64 (dirty yellow spot with ninhydrin-collidine) Λ

2098 12/17 402098 12/17 40

■·. Der Ester kann wie folgt in die freie 7-Aminoeephalo-.sporansäure übergeführt werden :_ man löst 6,8 g = 1 Teil Ester . in 1 Teil Anisol und versetzt mit 5 Teilen Trifluoressigsäure. Man dampft anschliessend sofort bei 0,2 mm Quecksilbersäule.■ ·. The ester can be converted into the free 7-aminoeephalo-sporic acid as follows: 6.8 g = 1 part of ester is dissolved. in 1 part of anisole and mixed with 5 parts of trifluoroacetic acid. You then immediately vaporize at 0.2 mm of mercury.

'innerhalb,20 Hinuten'ein, nimmt in JO ml Essigester auf und giesst die Lösung gleichzeitig mit ca. I3 ml 50-proz. wässriger Trikaliumphosphatlösung unter Rühren auf 20 ml-3-proz. wässrige- Dikaliumhydrogenphosphatlösung. Die beiden Zuflüsse sind dabei so .zu bemessen, dass das pH zwischen 6-8 pendelt und am Ende .auf 7 stehen bleibt. Die abgetrennte wässrige Phase wird noch 2mal-mit · je 10 mi/'Essigester·. ■"·' und die 3 Essigesterphasen werden 2mal mit je 5 ml j5-proz«. wässriger Dikaliumhydrogenphosphatlösung gewaschen. Man verwirft die organischen Phasen, vereinigt die wässrigen und stellt mit ca. k ml konz. Salzsäure auf pH 3,5.. Das' nach 15 Std. Stehen bei'0 abgeschiedene Produkt wird abfiltrlert, mit wenig Eiswasser gewaschen und getrocknet. Man erhält 3,90 g (= 92% d.Th.) reine 7-Amino-cephalosporansäure. 'within, 20 minutes' one, takes up ml of ethyl acetate in JO and pours the solution at the same time with approx. 13 ml of 50 percent. aqueous tripotassium phosphate solution with stirring to 20 ml-3 percent. aqueous dipotassium hydrogen phosphate solution. The two inflows are to be measured in such a way that the pH fluctuates between 6-8 and at the end of the day stays at 7. The separated aqueous phase is mixed twice with 10 ml / 'ethyl acetate each time. ■ "* 'and the 3 Essigesterphasen are washed 2 times with 5 ml j5-proz." Aqueous dipotassium hydrogen phosphate solution. It discards the organic phases are pooled, the aqueous and provides approximately k ml of conc. Hydrochloric acid to pH 3.5 .. The The product deposited after 15 hours of standing at 0 is filtered off, washed with a little ice water and dried, giving 3.90 g (= 92% of theory) of pure 7-amino-cephalosporanic acid.

209812/mO ' BADOWaiH«.209812 / mO 'BADOWaiH «.

Der als Ausgangsmaterial·verwendete Cephalosporin C-di-benzhydrylester kann wie folgt hergestellt werden:The cephalosporin C-di-benzhydryl ester used as starting material can be prepared as follows:

Eine Suspension von 4,82 g 85 $igem Cephalosporin C-Natriumsalz (♦ 2 HpO; 8,7 mMol) in 80 ml Methanol wird mit ΐβ,7 ml 1,5 n.-methanolischer Salzsäure versetzt und die klare Lösung bei 0,1 mm Hg eingedampft. Der Rückstand enthält rohes Cephalosporin G-hydrdchlorid, dass anschliessend I in 100 ml Dimethylformamid gelöst und mit 10 g Diphenyldiazome.than· 20 Minuten bei 20° verestert wird. Eindampfen, Digerieren mit Petroläther, Aufnehman in Essigester, Waschen.mit 10 Dikaliumphosphatlösung, Trocknen über Natriumsulfat und . Eindampfen im Vakuum ergibt 7,26 g (ca. 70 ^igen) Cephalosporin C-dibenzhydrylester als farblosen Schaum. Die Verbindung zeigt im Dünnschichtchromatogramm an Silicagel G folgende Rf-Werte: 0,65 im System n-Butanol-Eisessig(10:l) gesättigt mit Wasser; 0,78 im System n-Butanol-Pyridin-Eisessig-Was-' ser (38:24:8:30); 0,12 im System Toluol-Aceton (7:3); typisch rotvioletter Fleck mit Ninhydrin-Collidin. pK ^=6,35. * MCSA suspension of 4.82 g of 85% cephalosporin C sodium salt (♦ 2 HpO; 8.7 mmol) in 80 ml of methanol is mixed with ΐβ, 7 ml of 1.5 N-methanolic hydrochloric acid and the clear solution at 0. 1 mm Hg evaporated. The residue contains crude cephalosporin G hydrochloride that is then dissolved in 100 ml of dimethylformamide and esterified with 10 g of diphenyldiazome.thane for 20 minutes at 20 °. Evaporation, digestion with petroleum ether, absorption in ethyl acetate, washing with 10 dipotassium phosphate solution, drying over sodium sulfate and. Evaporation in vacuo gives 7.26 g (approx. 70%) of cephalosporin C-dibenzhydryl ester as a colorless foam. In the thin-layer chromatogram on silica gel G, the compound shows the following Rf values: 0.65 in the n-butanol-glacial acetic acid system (10: 1) saturated with water; 0.78 in the n-butanol-pyridine-glacial acetic acid-water system (38: 24: 8: 30); 0.12 in the toluene-acetone system (7: 3); typical red-violet spot with ninhydrin collidine. pK ^ = 6.35. * MCS

2 0 9812/17402 0 9812/1740

Claims (2)

Patentansprüche :Patent claims: 1. 7-Aminocephalosporansäurebenzhydrylester.1. 7-Aminocephalosporanic acid benzhydryl ester. 2. 7-Aminocephalosporansäurebenzhydrylester-(pjp-di· methoxy)-benzhydrylester^2. 7-Aminocephalosporanic acid benzhydryl ester (pjp-di methoxy) benzhydryl ester ^ 209812/1740 - offle(NAL 209812/1740 - offle (NAL
DE19641795590 1963-03-15 1964-03-11 7-Amino-cephalosporanic acid benzhydryl and p, p'-dimethoxybenzhydryl ester Expired DE1795590C3 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
CH329363A CH447172A (en) 1963-03-15 1963-03-15 Process for the preparation of 7-amino-cephalosporanic acid esters
CH329363 1963-03-15
CH406863 1963-03-29
CH406863 1963-03-29
CH492363 1963-04-19
CH492363 1963-04-19
CH126264 1964-02-04
CH126264 1964-02-04
BE645157A BE645157A (en) 1963-03-15 1964-03-13

Publications (3)

Publication Number Publication Date
DE1795590A1 true DE1795590A1 (en) 1972-03-16
DE1795590B2 DE1795590B2 (en) 1975-09-18
DE1795590C3 DE1795590C3 (en) 1976-04-29

Family

ID=

Also Published As

Publication number Publication date
NL145555B (en) 1975-04-15
SE313813B (en) 1969-08-25
DE1795590B2 (en) 1975-09-18
BE645157A (en) 1964-09-14
DE1445619A1 (en) 1969-09-25
GB1027750A (en) 1966-04-27
CH447172A (en) 1967-11-30
NL6402678A (en) 1964-09-16
DK118821B (en) 1970-10-12

Similar Documents

Publication Publication Date Title
DE2760156C2 (en)
DE2760287C2 (en)
DE1795590A1 (en) New 7-amino-cephalosporanic acid esters
DE1795590C3 (en) 7-Amino-cephalosporanic acid benzhydryl and p, p'-dimethoxybenzhydryl ester
DE1593315C (en)
DE2436332A1 (en) SUBSTITUTED TETRAHYDROFURANS AND PROCESS FOR THEIR PRODUCTION
AT261130B (en) Process for the production of the new 3.2 Dioxo 17α methyl 19 nor pregna 4,9,11 triens
DE3219407C2 (en)
DE1593315B1 (en) 9-isopropylidene-9,10-dihydroanthracene-10-carboxylic acid-ß-diaethylamino-ethyl ester, their salts and process for their preparation
DE931947C (en) Process for the preparation of 20, 21-pregnanketol esters
DE1618815B1 (en) Process for the preparation of 3-oxogona-4,9,11-trienes
CH281597A (en) Process for the production of an anhydro-corticosterone.
DE942926C (en) Process for the production of 11ª ‡ -oxy-17ª ‡ -methyltestosterone or 11ª ‡ -oxy-10-normethyl-17ª ‡ -methyltestosterone
AT295056B (en) Process for the production of the new 7α-methyl-3,16β, 17α-trihydroxy-Δ <1,3,5 (10)> - oestratriens
AT238382B (en) Process for the preparation of 17α-acyloxy-6α-methyl-16-methylenepregn-4-en-3,20-dione
AT233174B (en) Process for the preparation of 3-keto-Δ4, 6-10 (α) -methyl steroids
DE1643495C (en) 4 (8 carboxyoctyl) 1,3 dithra cyclopentan 2 ones or 2 thiones and process for their preparation
DE1593807C (en) alpha ascine methyl or ethy (ester, as well as a process for their production
DE1643018B2 (en) 4-CHLORINE-1,2-ALPHA-METHYLENE-DELTA HIGH 4,6-PRGNADIEN-17-ALPHA-OL-3,20-DIONE AND ITS 17-ESTERS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICALS CONTAINING THEM
AT247854B (en) Process for the preparation of new substituted malonic acid monohydrazides and their salts
DE2508965C2 (en) 1'-Desmethyl-1 '- (β-hydroxyethyl) -clindamycin-2-palmitate, its acid addition salts and process for their preparation
DE1618815C (en) Process for the preparation of 3 oxogona 4,9,11 tons
AT233176B (en) Process for the preparation of new 21-half esters of 3, 20-dioxo-21-hydroxypregnane compounds which are unsaturated in ring A
DE1029825B (en) Process for the preparation of 19-nortestosterone hexahydrobenzoate
DE2022695A1 (en) 21-phosphate pregnanes

Legal Events

Date Code Title Description
C3 Grant after two publication steps (3rd publication)
E77 Valid patent as to the heymanns-index 1977
EHV Ceased/renunciation